Identification of Pathogenic PD‐1+CD8+ T Cells for Effective Chimeric Antigen Receptor Therapy in a Murine Model of Sjögren Disease

Documenti analoghi

• B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis
  di: Shlomit Kfir‐Erenfeld, et al.
  Pubblicazione: (2026)
• Correction to CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus
  Pubblicazione: (2025)
• Living With Sjögren Disease: Prospects for Disease‐Modifying Therapies
  di: E. William St. Clair
  Pubblicazione: (2024)
• Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell–Targeted Therapy in the Trial of Anti–B Cell Therapy in Patients With Primary Sjögren Syndrome (TRACTISS)
  di: Elena Pontarini, et al.
  Pubblicazione: (2024)
• Impact of IgG Fc Glycosylation on Disease Dynamics in Patients With Primary Sjögren Disease
  di: Helena Achten, et al.
  Pubblicazione: (2024)